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Background: Among rare channelopathies BrS patients are at high risk of sudden
cardiac death (SCD). SCN5A mutations are found in a quarter of patients. Other rare
gene mutations including SCN1B have been implicated to BrS. Studying the human
cellular phenotype of BrS associated with rare gene mutation remains lacking.
Objectives: We sought to study the cellular phenotype of BrS with the
SCN1B gene variants using human-induced pluripotent stem cell (hiPSCs)–derived
cardiomyocytes (hiPSC-CMs).
Methods and Results: A BrS patient suffering from recurrent syncope harboring a two
variants (c.629T> C and c.637C> A) in SCN1B, which encodes the function-modifying
sodium channel beta1 subunit, and three independent healthy subjects were recruited
and their skin biopsies were used to generate hiPSCs, which were differentiated into
cardiomyocytes (hiPSC-CMs) for studying the cellular electrophysiology. A significantly
reduced peak and late sodium channel current (INa) and a shift of activation curve to
more positive potential as well as a shift of inactivation curve to more negative potential
were detected in hiPSC-CMs of the BrS patient, indicating that the SCN1B variants
impact the function of sodium channels in cardiomyocytes. The reduced INa led to a
reduction of amplitude (APA) and upstroke velocity (Vmax) of action potentials. Ajmaline,
a sodium channel blocker, showed a stronger effect on APA and Vmax in BrS cells as
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compared to cells from healthy donors. Furthermore, carbachol was able to increase
arrhythmia events and the beating frequency in BrS.
Conclusion: Our hiPSC-CMs from a BrS-patient with two variants in SCN1B
recapitulated some key phenotypic features of BrS and can provide a platform for
studies on BrS with SCN1B variants.
Keywords: Brugada, sudden cardiac death, channelopathy, genetic, sodium channel
INTRODUCTION
Sudden cardiac death (SCD) is related to ventricular
tachyarrhythmias. Right bundle branch block and coved
ST-segment elevation in precordial leads (V1 to V3) at baseline
or after using sodium channel blocking drug are diagnostic
markers of Brugada syndrome (BrS). In addition, fever could
potentially unmask BrS. Therefore a consensus statement of
the ESC guideline 2015 recommended avoiding fever and/or
infections as a trigger of BrS and/or arrhythmias (Casado-Arroyo
et al., 2016). BrS patients and their families are at risk to develop
malignant ventricular tachyarrhythmias and SCD (Morita
et al., 2002). BrS patients may have other symptoms including
recurrent syncope and atrial arrhythmias. In men <40 years old
BrS is a denominator cause of SCD.
More than 300 mutations in 12 genes, mainly in SCN5A
(encoding the ion channel Nav 1.5), have been reported in
more than a quarter of patients (Risgaard et al., 2013). The
relation of further genes including SCN1B (encoding the
sodium channel beta1 subunit) has been debated (Hu et al.,
2009). Due to the lack of suitable human cardiomyocyte
models for the majority of gene mutations, mimicking the
key features of BrS, their genotype-phenotype association is
controversial. Recently published data from human induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
from BrS patients in the presence of mutations in SCN5A
demonstrated a successful establishment of a cellular BrS
model and confirmed experimentally the genotype-phenotype
association of SCN5A mutations versus BrS (Liang et al.,
2016). In 2008, the first report about the role of SCN1B in
BrS was published (Watanabe et al., 2008). Watanabe et al.
recruited 326 patients suffering from BrS and conduction
disease and investigated the presence of SCN1B mutations. In
that study mutations in SCN5A have been excluded. Three
mutations (c.259G > C, c.536G > A, c.537G > A) in
SCN1B were identified in three families. A co-expression of
mutant beta1 or beta1B subunits in CHO cells with Nav 1.5
showed a lower sodium channel current as compared with a
co-expression with wild type subunits of SCN1B. Those data
suggested an important role of SCN1B for cardiac sodium
channel current and an association of SCN1B mutations with
BrS. But until now, cellular models of BrS with SCN1B
mutations remain lacking.
In BrS patients a cardioverter defibrillator (ICD) for secondary
prevention is recommended. Of note, ICD is associated with
a bevy of complications. Therefore, pharmacotherapy is also
required, at least for some patients. Models of BrS are warranted
for drug screening and/or studying the pathomechanisms of
ventricular tachyarrhythmias in BrS.
Recently published data demonstrated that hiPSC-CMs are
useful for research on pathophysiology of cardiac disorders (El-
Battrawy et al., 2016). Ion channel characteristics and action
potential characteristics of hiPSC-CMs are comparable to human
ventricular cardiomyocytes (Zhao et al., 2018). Additionally,
different diseases have been studied using hiPSC-CMs, making
these cells suitable for further research in cardiomyopathies and
channelopathies (Moretti et al., 2010; El-Battrawy et al., 2016,
2018a,b,c,d; Liang et al., 2016; Yucel et al., 2017). Based on those
reports, we aimed to study the cellular phenotype of a BrS patient
in presence of a compound mutation in the SCN1B using hiPSC-
CMs and provide a cellular model of BrS with SCN1B mutations
for further pathophysiology and drug screening studies.
MATERIALS AND METHODS
Ethics Statement
One BrS patient and three healthy donors were recruited for
skin biopsy after obtaining a written informed consent. The
Ethics Committee of the Medical Faculty Mannheim, University
of Heidelberg (approval number: 2018-565N-MA) and the Ethics
Committee of University Medical Center Göttingen (approval
number: 10/9/15) have approved the study, which was carried out
in accordance with the guidelines of Helsinki Declaration of 1975,
as revised in 1983.
DNA-Sequencing Analysis
DNA was isolated from blood lymphocytes. Ninety-eight of
107 coding exons of the genes CACNA1C, CACNB2, GPD1L,
KCNE3, SCN1B, SCN3B, SCN10A, and SCN5A including
exon/intron boundaries were amplified by PCR and subjected to
bidirectional Sanger sequencing. Sequences were mapped against
hg19 references (NM_015141.3, NM_000719.5, NM_201590.2,
NM_199037.4, NM_005472.4, NM_018400.3, NM_006514.3,
and NM_198056.2) via JSI Sequence Pilot for further analysis.
Generation of Human iPS Cells
Human iPS cells (hiPSCs) were generated from primary
human fibroblasts derived from skin biopsies. The BrS cell
lines isBrSc2.5, isBrSc2.15, and isBrSc2.16 (UMGi128-A) from
the index patient were generated in feeder free culture
conditions using the integration-free CytoTune-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher Scientific) with the
reprogramming factors OCT4, KLF4, SOX2, c-MYC according
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to the manufacturer’s instructions with modifications. The
generated hiPSCs were characterized for their pluripotency
and their in vitro differentiation potential as described (El-
Battrawy et al., 2018a,b,c). The cell line from the first healthy
donor (D1) was generated using lentiviral particles carrying
the transactivator rtTA and an inducible polycistronic cassette
containing the reprogramming factors OCT4, SOX2, KLF4
and c-MYC and was described previously (El-Battrawy et al.,
2018a,b). The cell lines from the second and third healthy donor
(UMGi014-B and UMGi124-A, abbreviated as D2 and D3) were
generated in feeder free culture conditions using the integration-
free episomal 4-in-1 CoMiP reprogramming plasmid (Addgene,
#63726) with the reprogramming factors OCT4, KLF4, SOX2,
c-MYC and short hairpin RNA against p53 or the integration-
free CytoTune-iPS 2.0 Sendai Reprogramming Kit, respectively,
and were described previously (El-Battrawy et al., 2018a,c).
Newly established iPSC lines were passaged with Versene
Solution (Thermo Fisher Scientific) and cultured in StemMACS
iPS-Brew XF medium (Miltenyi Biotec) supplemented with
2 µM Thiazovivin (Merck Millipore) on the first day after
passaging in Matrigel-coated plates for at least ten passages before
being used for pluripotency characterization and differentiation
experiments. Two independent cell lines from each healthy donor
were used for experiments and no differences were observed
between these cell lines.
For embryoid body (EB) formation, 5 × 104 iPSCs together
with 2.5 × 104 mouse embryonic fibroblasts were plated
in each well of a 96-well U-bottom plate in hES medium
composed of DMEM-F12 (Thermo Fisher Scientific), 15%
Knockout Serum Replacement (Thermo Fisher Scientific), 1×
MEM Non-Essential Amino Acids Solution (Thermo Fisher
Scientific), 50 µM β-mercaptoethanol (SERVA Electrophoresis)
and 2 µM Thiazovivin, the plate was centrifuged at 250 g
for 5 min and co-cultures were cultivated in suspension to
form multicellular EB aggregates. At d2, medium was changed
to differentiation medium composed of IMDM GlutaMAX
(Thermo Fisher Scientific), 20% Fetal Bovine Serum (Thermo
Fisher Scientific), 1×MEM Non-Essential Amino Acids Solution
and 450 µM 1-Thioglycerol (Sigma-Aldrich) for further 6 days
with medium change every other day. At d8, EBs were plated
onto 0.1% gelatin-coated 6-well plates and cultured for up to
one month in differentiation medium with medium change
every other day.
Generation of hiPSC-CMs
Frozen aliquots of hiPSCs were thawed, cultured without
feeder cells and differentiated into hiPSC-CMs as described
with some modifications (El-Battrawy et al., 2016; Cyganek
et al., 2018). Briefly, the hiPSCs are maintained in E8
medium (STEMCELL Technologies) supplemented with human
albumin and ascorbic acid. Then the directed differentiation
of hiPSCs into cardiomyocytes (hiPSC-CMs) is initiated at
80–90% confluence in 24-well plates with Matrigel coated.
The cardiomyocyte differentiation medium composes of RPMI
1640 with GlutaMAX and HEPES (Thermo Fisher Scientific),
0.5 mg/ml human recombinant albumin, 0.2 mg/ml L-ascorbic
acid 2-phosphate and 1% Pen/Strep. For the differentiation the
hiPSCs are sequentially treated with 4 µM CHIR99021 (Merck
Millipore) for 48 h and then 5 µM IWP2 (Merck Millipore)
for 48 h with the cardiomyocyte differentiation medium. The
medium is changed to cardiomyocyte culture medium composed
of RPMI 1640 with GlutaMAX, HEPES, 2% B27 (Thermo Fisher
Scientific) and 1% Pen/Strep at day 8. Differentiated cells are
glucose-starved and supplemented with 5 mM sodium DL-
lactate to metabolically select hiPSC-CMs around day 13–15. The
selected iPSC-CMs are cultured in maintenance media at least to
day 40–60 for further maturation.
In our lab the differentiation of hiPS cells into cardiomyocytes
(hiPSC-CMs) is regularly performed every 2 to 3 weeks. The
beating hiPSC-CMs from different independent differentiations
were used for studies and the data were combined. At
40 to 60 days after start of differentiation, cardiomyocytes
were dissociated from 24 well plates and plated as single
cells on Matrigel-coated 3.5 cm petri dishes for patch-clamp
measurements and calcium transient measurements.
Immunocytochemical Staining and Flow
Cytometry of iPSCs and iPSC-CMs
Human-induced pluripotent stem cell cultures were fixed with
Roti-Histofix 4% (Carl Roth) at RT for 20 min and blocked
with 1% bovine serum albumin (BSA; Sigma-Aldrich) in PBS
at 4◦C overnight. Primary antibodies were applied in 1% BSA
for 1 h at 37◦C or overnight at 4◦C. Secondary antibodies with
minimal cross reactivity were administered in 1% BSA for 1 h
at RT. For nuclear or cytosolic proteins (OCT4, SOX2, NANOG,
LIN28), cells were permeabilized with 0.1% Triton-X100 (Carl
Roth) in staining solution. Nuclei were stained with 4.8 µM
DAPI (Thermo Fisher Scientific) for 10 min at RT. Samples
were mounted in Fluoromount-G (Thermo Fisher Scientific).
Antibodies and dilutions used were listed in Supplementary
Table S3. Images were collected using the Axio Observer Z1
microscopy system (Carl Zeiss) with AxioCam MRm, Plan-
Apochromat 20×/0.8 objective or A-Plan 10×/0.25 objective and
AxioVision software.
For flow cytometry analysis, cells were dissociated into single
cells, fixed in Roti-Histofix 4% at RT for 20 min and blocked with
1% BSA in PBS at 4◦C for at least 2 h. iPSCs were permeabilized
with 0.1% Triton-X100 in staining solution and co-incubated
with fluorescence-conjugated antibodies against OCT4 and TRA-
1-60 at RT for 1 h. Nuclei were co-stained with 8.1 µM
Hoechst 33342 (Thermo Fisher Scientific). Subsequently, cells
were analyzed using the LSRII flow cytometer (BD Biosciences)
and BD FACSDiva software. Gating of cells was applied based on
forward scatter area (FSC-A) and sideward scatter area (SSC-A)
as well as on gating of single cells (based on DNA signal width).
At least 10,000 events were analyzed per sample.
The iPSC-CMs are dissociated from 24-well plates and
plated onto the culture slides (354114; Thermo Fisher Scientific,
Waltham, MA, United States). All slides are fixed with
4% paraformaldehyde at room temperature for 10 min and
permeabilized with 0.5% triton for 10 min. After blocking in
5% bovine serum albumin (BSA, 10270106; Thermo Fisher
Scientific, Waltham, MA, United States) for 30 min, the
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slides are incubated in primary antibodies at 4◦C, and then
are incubated with the second antibodies Anti-rabbit/mouse
IgG (H + L), F(ab’)2 Fragment (1:2000; Cell Signaling,
United States). The primary antibodies used on hiPSC-CMs
are monoclonal Anti-α-Actinin (Sarcomeric) (A7811, 1:200;
Sigma-Aldrich, Merck KGaA, Darmstadt, Germany), Anti-
Cardiac Troponin T antibody [1C11] (ab8295, 1:200; Abcam,
Cambridge, United Kingdom) and Anti-Myl4 (A20170301415,
1:100, Cloud-Clone, United States). Three random fields per wells
(at least 10 cells) are photographed and the immunofluorescence
density of the positive staining per field is measured by
Image J software.
Polymerase-Chain-Reaction Assays
To quantify the steady-state mRNA expression of ion channels
from the hiPSC-CMs, RNA was prepared, reverse transcribed
and qPCR was performed as described (El-Battrawy et al.,
2016). Gene symbols, RefSeq No. and Cat. No. of the primers
used for qPCR analyses in hiPSC-CMs characterization were
listed in the Supplementary Table S1. For evaluation of the
characteristics of the used hiPSC lines, RT-PCR was performed
as follows: Total RNA was isolated using the SV Total RNA
Isolation System (Promega, #Z3105) according to manufacturer’s
instructions. 100 ng RNA was used for the first-strand cDNA
synthesis by using MULV Reverse Transcriptase (Thermo
Fisher Scientific, #N8080018) and Oligo d(T)16 (Thermo Fisher
Scientific, #N8080128). One-tenth of cDNA was used as PCR
template and amplified using the GoTaq G2 DNA polymerase
(Promega, #M7845) according to manufacturer’s instructions.
Primer sequences, annealing temperatures and cycles used
for RT-PCR analyses of the hiPSC lines are listed in the
Supplementary Table S2.
Western Blot
The hiPSC-CMs were lysed using RIPA-buffer (Sigma-Aldrich)
with Protease- and Phosphatase Inhibitors (Sigma-Aldrich)
added. The protein concentration was measured using the
BCA-method (Thermo Scientific). For Western blot a 10%
(1 mm) SDS-PAGE (Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis) and PVDF (polyvinylidene difluoride)
membrane were used. As protein markers Precision Plus (Bio-
Rad) and LMW (GE Healthcare/Amersham) were utilized. The
membrane was blocked with a solution of 5% non-fat milk
powder in 0.1% TBS-T buffer. As primary antibodies we used
SCN5A (Abcam Cat. No ab56240), SCN1B [Abcam (Cat. No.
ab107370), GAPDH (HyTest Ltd., Cat. No 5G4) and conjugated
secondary antibody (Sigma-Aldrich Cat. NoA0545 (Anti-Rabbit
IgG) and A3682 (Anti-Mouse IgG)]. Before taking pictures with
the Fuji LAS 1000 imager, the immunoblots were enhanced
with West Femto maximum sensitivity substrate (SuperSignal R©,
Thermo Scientific). The analysis of pixel density was performed
using an AIDA image analyzer (v4.25).
Patch-Clamp
After harvesting beating cardiomyocytes after 40 days standard
patch-clamp recording techniques were used to measure action
potential (AP) and different ion channel currents including
transient outward potassium current (Ito), slowly activating
delayed rectifier potassium current (Iks), rapidly activating
delayed rectifier potassium current (Ikr), peak and late sodium
(INa), and L-type calcium (ICaL) channel currents in the
whole-cell configuration. All studies were carried out at
room temperature. From the inactivation curves of sodium
channel currents, we know that at −80 mV about 50%
and at −60 mV almost 100% of sodium channels are
inactivated. Without current injection, most cells displayed
a resting potential (RP) of around −60 mV or even less,
meaning that the recorded action potentials (AP) in those cells
contain no effects of sodium channel currents. APs without
contribution of sodium channel currents cannot represent
APs of cardiomyocytes. Therefore a constant inward current
was injected to hyperpolarize cells to around −80 mV and
APs were evoked by pulses with fixed frequencies. To check
the real RPs in hiPSC-CMs, we recorded also RPs without
current injection.
The bath solution for peak sodium current (INa)
measurements contained (mmol/L): 20 NaCl, 110 CsCl, 1.8
CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, 0.001 nifedipine, pH
7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10
NaCl, 135 CsCl, 2 CaCl2, 3 MgATP, 2 TEA-Cl, 5 EGTA, 10
HEPES, pH7.2 (CsOH).
The bath solution for late sodium current contained (mmol/l):
135 NaCl, 20 CsCl, 1.8 CaCl2, 1 MgCl2, 10 Hepes, 10 glucose,
0.001 nifedipine, pH 7.4 (CsOH). Microelectrodes were filled
with (mmol/l): 10 NaCl, 135 CsCl, 2 CaCl2, 3 MgATP, 2 TEA-Cl,
5 EGTA and 10 HEPES (pH7.2 CsOH).
The bath solution for ICaL recordings contained (mmol/l):
140 TEA-Cl, 5 CaCl2, 1 MgCl2, 10 Hepes, 0.01 TTX, 2 4-AP,
pH 7.4 (CsOH). Microelectrodes were filled with (mmol/l): 10
NaCl, 135 CsCl, 2 CaCl2, 3 MgATP, 2 TEA-Cl, 5 EGTA and 10
HEPES (pH7.2 CsOH).
The bath solution (PSS) for Ito, IKs, and AP measurements
contained (mmol/l): 130 NaCl, 5.9 KCl, 2.4 CaCl2, 1.2 MgCl2, 11
glucose, 10 HEPES, pH 7.4 (NaOH). For the Ito measurements,
10 µM nifedipine, 10 µM TTX and 1 µM E-4031 were added
in the bath solution to block ICaL, INa and IKr. 4 AP was used to
identify Ito (the 4 AP-sensitive current). For IKs measurements
1 µM E-4031 was added. Chromanol 293B (10 µM) was used to
isolate IKs from other currents. The pipette solution contained
(mmol/l): 10 HEPES, 126 KCl, 6 NaCl, 1.2 MgCl2, 5 EGTA, 11
glucose and 1 MgATP, pH 7.2 (KOH).
To improve IKr measurements, the Cs2+ currents conducted
by the KCNH2 (IKr) channels were measured. External solution
for Cs2+ currents (mmol/L): 140 CsCl, 2 MgCl2, 10 HEPES, 10
Glucose, pH = 7.4 (CsOH). Pipette solution: 140 CsCl, 2 MgCl2,
10 HEPES, 10 EGTA, pH = 7.2 (CsOH).
Measurement of Intracellular Calcium
Concentration
To measure the intracellular Ca2+ concentration ([Ca2+]i), cells
were loaded with the fluorescent Ca2+-indicator Fluo-3 AM. The
fluorescence of the cells was measured by using a Cairn OptoScan
calcium imaging system (Cairn Research, United Kingdom).
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Fluorescence is excited by 488 nm and emitted at 520 nm.
Changes in [Ca2+]i were described by
[Ca2+]i = kd
(
F
Fmax − F
)
(1)
where kd = dissociation constant of Fluo-3 (400 nmol/L),
F = Fluo-3 fluorescence, Fmax = Ca2+-saturated fluorescence
obtained at the end of each experiment (Trafford et al., 1999).
Statistical Analysis
Data were analyzed using InStat© (GraphPad, San Diego, CA,
United States) and SigmaPlot 11.0 (Systat GmbH, Germany).
They are presented as mean ± SEM. Kolmogorov–Smirnov
test was used to find out if parametric or non-parametric
tests are required. One-way ANOVA with Bonferroni post-
test was indicated in comparisons of parametric data, whereas
the Kruskal–Wallis test with Dunn’s multiple comparisons
post-test was indicated for non-parametric data. Student’s
t-test was used for comparison of variables with normal
distribution. Mann–Whitney U-test was used for comparison
of variables with non-normal distributions, respectively. Paired
t-test was used for qualified data comparison (before and
after application of a drug). Two-tailed p < 0.05 was
considered significant.
RESULTS
Characterization of Patient Specific
hiPSCs and hiPSC-CMs
A 48 years old male patient with syncope at resting
situation, carrying two variants (c.629T > C/p.L210P and
c.637C > A/p.P213T) in SCN1B (Figure 1A), was included
in our study. BrS ECG was unmasked after using ajmaline
as a diagnostic challenge (Figure 1B). The family pedigree is
illustrated in Figure 1C. A cascade family screening was carried
out by our team excluding a structural cardiac disease and
identified BrS in one son of the patient. BrS was diagnosed
in his son using ajmaline to unmask BrS ECG. His son
was asymptomatic. No history of sudden cardiac death was
documented in the whole family. No information of other
relatives or family members was available.
Dermal skin fibroblasts of the patient were successfully
reprogrammed into iPSCs and three independent patient-
specific iPSC lines were characterized for pluripotency. Control
iPSC lines D1-D3 have been previously studied and deeply
characterized in our previous studies (El-Battrawy et al.,
2016, 2018a,b,c). The hiPSCs from the BrS-patient displayed
characteristic human embryonic stem cell (ESC) morphology
and expression of pluripotency markers (Figures 2A–D and
Supplementary Figure S1A). Additionally, spontaneous
differentiation of the generated hiPSC lines via embryoid bodies
confirmed expression of germ layer-specific genes from all three
FIGURE 1 | (A) Sanger sequencing of patient-derived cells confirmed the presence of the SCN1B variants c.629T > C/p.L210P and c.637C > A/p.P213T. (B) An
ECG of the patient before and after receiving ajmaline (1 mg/kg) presents typical BrS changes. (C) A family pedigree presents the affected patient and his affected
son. Both persons have the same affected gene mutations in SCN1B as described in panel (A).
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FIGURE 2 | (A) The generated iPSC lines isBrSc2.5, isBrSc2.15, and isBrSc2.16 derived from skin fibroblasts of the BrS patient (BrSc2 Fibro) display a typical
morphology for human pluripotent stem cells (upper panel) and are positive for alkaline phosphatase as being upregulated in pluripotent stem cells (lower panel).
Scale bar: 100 µm. (B) In comparison to donor’s fibroblasts, generated iPSC lines show expression of pluripotency markers OCT4, SOX2, NANOG, LIN28, FOXD3,
and GDF3 at mRNA level proven by RT-PCR. Human embryonic stem cells (hESCs) were used as positive control, mouse embryonic fibroblasts (MEFs) were used
as negative control. (C) Flow cytometry analysis of pluripotency markers OCT4 and TRA-1-60 reveals a homogeneous population of pluripotent cells in generated
iPSC lines. (D) Generated iPSC lines express pluripotency markers OCT4, SOX2, NANOG, LIN28, SSEA4 and TRA-1-60 as shown by immunofluorescence staining.
Nuclei are co-stained with DAPI. Scale bar: 100 µm. (E) Spontaneous differentiation potential of generated iPSC lines was analyzed by embryoid body formation.
Immunocytochemical staining of spontaneously differentiated iPSC lines shows expression of endodermal marker AFP, mesodermal-specific α-SMA and ectodermal
βIII-tubulin. Nuclei are co-stained with DAPI. Scale bar: 100 µm.
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germ layers (Figure 2E). The presence of the two SCN1B variants
as shown in Figure 1A was verified in all characterized hiPSC
lines from the patient (data not shown).
Three clones of hiPSCs from the BrS-patient (BrS) and
control lines (D1, D2 and D3) were differentiated into functional
hiPSC-CMs in feeder-free culture conditions for subsequent
functional analyses. Beating cardiomyocytes were observed
8–12 days after starting the differentiation. The mRNA level
of cTnT was similarly increased over time in all cell lines
(Supplementary Figure S1B). Cardio-specific markers including
α-actinin, Myl4 and cTnT were detected by immunostaining
(Supplementary Figure S1C) as published in other papers
(El-Battrawy et al., 2018a,c).
Changes in Ion Channel Expression in
hiPSC-CMs From the BrS-Patient
The qPCR analysis was used for investigating the mRNA
expression levels of different ion channels and some receptors.
BrS cells showed that the mRNA levels of the ion channel SCN5A
and ß2-adrenoceptor were increased compared to donor cells,
but the mRNA expressions of CACNA1C, KCNJ2, KCNH2,
FIGURE 3 | Peak INa was reduced in hiPSC-CMs from the BrS-patient. Peak INa was recorded with the protocol shown in panel A (inset) in hiPSC-CMs from donors
(D1, D2, D3) and the BrS patient. The measured peak currents were plotted against voltages to obtain the current-voltage relationship (I-V) curves. INa was divided
by the driving force (V-Vres, where V presents the voltage at each step, Vres represents the reverse potential for Na+ current) to obtain the conductance (G), which is
in turn normalized to maximum (G/Gmax) and plotted against voltages to obtain the activation curves. For assessing the inactivation of sodium channels INa was
recorded with the protocol indicated in I (inset) and the inactivation curves were obtained. Both activation and inactivation curves were fitted by Boltzmann equation
to get the values of 50% activation or inactivation (V0,5) of sodium channels. For assessing the recovery of the channel INa was recorded with the double-pulse
protocol (inset in panel K). The currents evoked by the second pulse were normalized to that evoked by the first pulse and then plotted against the time intervals
between the two pulses. The recovery curves were fitted by single exponential equation to get the time constant (tau). (A–D) Representative traces of INa in
hiPSC-CMs from healthy donors and the BrS patient. (E,F) I-V curves and INa at –40 mV showing a reduced peak INa in hiPSC-CMs from donors and the BrS
patient. (G,H) Activation curves and the voltage values at 50% activation (V0.5). (I,J) Inactivation curves and the voltage values at 50% inactivation (V0.5). (K,L)
Curves and tau values of recovery from inactivation. n, number of cells.
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SCN1B and SCN3B as well as ß1-adrenoceptor were lower
than in donor cells (Supplementary Figures S1D,E). Western
blot analysis showed a similar protein level of SCN5A but a
reduced SCN1B level in BrS cells compared to healthy donor cells
(Supplementary Figures S2A,B).
Changes of INa in hiPSC-CMs From the
BrS-Patient
Peak and late sodium current INa were significantly reduced
in BrS cardiomyocytes as compared to control cells (peak INa,
BrS −19.3 ± 3.7 pA/pF versus D1 −116.9 ± 28.7 pA/pF, D2
−95.4 ± 41.6pA/pF and D3 −94.7 ± 28.3 pA/pF; late INa,
BrS −0.2 ± 0.03pA/pF versus D1 −0.4 ± 0.06 pA/pF, D2
−0.4 ± 0.08 pA/pF and D3 −0.3 ± 0.06pA/pF; Figure 3 and
Supplementary Figures S2C,D). While the activation curves of
INa of BrS were shifted to more positive potentials (V0.5 BrS
−37.8 ± 1.8 mV versus D1 −53.2 ± 2.1, D2 −43.3 ± 2.1,
and D3 −45.1 ± 4.1 mV; Figures 3G,H), the inactivation curve
was significantly shifted to more negative potentials (V0.5, BrS
−88.1 ± 1.8 mV versus D1 −73.7 ± 2.3, D2 −80.6 ± 1.5,
and D3 −77.9 ± 2.6 mV; Figures 3I,J) and the recovery of
INa from inactivation was conspicuously decelerated in BrS
cardiomyocytes (Figures 3K,L).
Changes of L-Type Calcium Channel
Current (ICa−L) in hiPSC-CMs From the
BrS-Patient
The peak ICa−L in BrS cardiomyocytes was similar to that
in healthy cardiomyocytes (BrS, −7.4 ± 2.4pA/pF; D1,
−8.0 ± 1.4 pA/pF; D2, −8.4 ± 1.9 pA/pF; D3, 6.5 ± 1.3
pA/pF; Supplementary Figures S3A–C), which is consistent
with the findings that activation and inactivation were
not changed (Supplementary Figures S3D–G). However,
recovery from inactivation was conspicuously decelerated
in BrS cardiomyocytes as compared to healthy donor cells
(Supplementary Figures S3H,I).
In addition, by measuring the Ca2+ transients the intracellular
calcium concentration and calcium homeostasis was examined.
The systolic and diastolic concentrations in BrS cells were similar
to that in healthy cardiomyocytes (Supplementary Figure S4).
Changes of K+ Channel Currents in
hiPSC-CMs From the BrS-Patient
K+ channel currents are debated to contribute to
arrhythmogenesis in BrS. We studied the major K+ channel
current contributors in cardiomyocytes, the transient outward
FIGURE 4 | Changes of action potential in hiPSC-CMs from the BrS patient. Action potentials (AP) were evoked by pulses of 1 nA for 3 ms at 1 Hz in current clamp
mode. When APs reached steady state, 10 sequential APs were recorded and mean values were calculated for each cell. All the parameters of APs were compared
between cells from donors (D1, D2, D3) and the BrS patient. (A) Representative traces of APs in donor cells (D1, D2, and D3) and BrS cells. (B) Mean values of
maximal depolarization velocity (Vmax) of action potentials. (C) Mean values of action potential amplitude (APA). (D) Mean values of resting potentials (RP). (E) Mean
values of action potential duration at 50% repolarization (APD50). (F) Mean values of action potential duration at 90% repolarization (APD90). n, number of cells; n.s.,
not statistically significant (p > 0.05).
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current (Ito), the rapidly activating delayed rectifier potassium
current (IKr) and slowly activating delayed rectifier potassium
current (IKs) using specific blockers as described previously
(El-Battrawy et al., 2018c). The different K+ currents in BrS-
and donor-cells were identified using 4-AP for Ito, E-4031 for IKr
and chromanol 293B for IKs. Although the Ito was not changed,
both the IKs (BrS 0.1 ± 0.09 pA/pF versus D1 0.7 ± 0.2 pA/pF
and D2 0.7 ± 0.3 pA/pF) and the IKr (BrS 1.1 ± 0.2 pA/pF
versus D1 2.5 ± 0.25 pA/pF and D2 2.2 ± 0.4 pA/pF) were
significantly reduced in BrS cells as compared to healthy donor
cells (Supplementary Figure S5).
Action Potential in hiPSC-CMs
Action potential characterizations at 1 Hz are outlined in
Figure 4. Consistent with the reduced peak INa, a major
contributor of phase 0 of action potential, the action potential
amplitude (APA) and maximum depolarization velocity (Vmax)
were significantly reduced in BrS as compared to healthy
donors (Figures 4A–C). The other action potential characteristics
including the resting potential (RP), the action potential duration
at 50% repolarization (APD 50) and action potential duration
at 90% repolarization (APD 90) were similar in the measured
hiPSC-CMs from the patient and healthy donors.
Differential Effects of Ajmaline on Action
Potentials in Control and BrS Cells
To check whether ajmaline, a sodium channel current blocker
that is frequently used to unmask the phenotypic changes in
ECG of BrS-patients, implicates any changes in action potential
characterization, 30 µM ajmaline were used to test its effect on
APs at different frequencies. APs in same cells were measured
sequentially from 0.2 to 3 Hz (0.2, 1, 2, 3 Hz) before and after
ajmaline administration. Ajmaline reduced APA and Vmax in
both donor and BrS cells. However, the effects of ajmaline in
BrS cells is stronger than that in donor cells, especially at high
frequencies (Figure 5), indicating a higher sensibility of BrS cells
to ajmaline application.
Arrhythmogenity of BrS Cardiomyocytes
To check whether arrhythmia like events existed in BrS
cardiomyocytes, spontaneous beating cells were measured at
baseline and after addition of carbachol. Indeed, at baseline
arrhythmia like events occurred more frequently in BrS
cells than in donor cells (BrS: 11/13, D1: 12/24, D2: 6/16;
p < 0.05; Figures 6A,B). Interestingly, after adding carbachol,
a parasympathetic stimulator, donor cells showed a reduction
of the beating frequency, whereas the BrS cells showed an
increase in the beating frequency with arrhythmia-like events
(Figures 6C,D, 7A,B). These data are consistent with the high
risk of ventricular tachyarrhythmias observed in BrS patients at
resting situations.
DISCUSSION
We report here the first model of patient specific induced
pluripotent stem cell derived cardiomyocytes from a patient
FIGURE 5 | Enhanced effects of ajmaline on action potentials in hiPSC-CMs
from the BrS patient. Different frequencies of stimulations were used to evoke
APs. Effects of ajmaline (30 µM) on AP parameters were assessed in BrS-
and donor-cells. The percent inhibition of APA and Vmax was obtained by: %
inhibition = (Vctr–Vdrug)/Vctr × 100, where Vctr is the value before drug
application and Vdrug is the value after drug application. (A) Percent inhibition
of action potential amplitude (APA) by ajmaline in BrS- and donor-cells.
(B) Percent inhibition of maximal depolarization velocity (Vmax) of action
potentials by ajmaline in BrS- and donor-cells. In each, the BrS and control
(D3) group, 12 cells were measured ∗p < 0.05; ∗∗p < 0.01.
carrying two variants in the SCN1B gene with BrS diagnosed
by ajmaline administration. We found in BrS-hiPSC-CMs:
(i) The variants in SCN1B (c.629T > C/p.L210P and
c.637C > A/p.P213T) led to a loss of function of sodium
channels showing a significant reduction of APA and Vmax
as well as sodium channel currents resulted from reduction
of activation and enhancement of inactivation as well as
decelerated recovery from inactivation of sodium channels;
(ii) BrS-hiPSC-CMs displayed higher sensitivity responding to
ajmaline and carbachol showing enhanced changes of action
potential characteristics and increased arrhythmia events.
It is known that mutated SCN5A is a major contributor
of BrS. However, only 20–30% of BrS patients present
mutations of SCN5A. Recently published data reported that
other mutations, including SCN1B are also associated with the
clinical phenotype of BrS (Watanabe et al., 2008; Hu et al.,
2012). Additionally, variants in SCN1B have been also related
to atrial fibrillation and cardiac conduction dysfunction. But
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FIGURE 6 | Increased frequency and arrhythmia-like events in BrS-cardiomyocytes. Single cell calcium transients were recorded in spontaneously beating cells with
and without challenge by 10 µM carbachol. The rhythm (frequency, regularity, EAD- and DAD-like triggered activities) of beating cells were assessed and compared
between BrS- and donor-cells. (A) Proportions of cells showing arrhythmia events at baseline. (B) Representative Ca2+ transients in a donor and a BrS at baseline.
(C) Proportions of cells showing CCh-induced enhancement of beating frequency. (D) Beating frequencies of cells in the presence of 10 µM CCh showing
CCh-induced increase in beating frequency. Values given are mean ± SEM; n, number of cells.
their roles in arrhythmogenesis have not been investigated yet.
In the present study, we identified a genetic variant in SCN1B
(c.629T > C and c.637C > A) in a family with BrS. The
c.629T> C variant has been related to BrS (Ricci et al., 2014), but
the genotype-phenotype correlation has not been experimentally
confirmed. Whether the other one (c.637C > A) is relating
to BrS is not known. The variant NM_199037.4:c.629T > C
(dbSNP: rs55742440) is expected to result in the substitution of
leucine to proline at amino acid position 210 (Leu210Pro) of
the ß1B subunit of various sodium channels including Nav1.5.
The variant Leu210Pro was observed in 78326 out of 207962
(37.66%) alleles from individuals of various ancestry in the
Genome Aggregation Database (Lek et al., 2016). Due to the high
allele frequency and the high number of homozygotes carrying
this variant in population (Exac browser) L210P is evaluated
as “benign”1. The variant NM_199037.4:c.637C > A (dbSNP:
1http://exac.broadinstitute.org/variant/19-35524824-T-C
rs766373298) is expected to result in the substitution of proline
to threonine at codon 213 (Pro213Thr). The variant Pro213Thr
was observed in 2 out of 79668 (0.003%) alleles from individuals
of European (Non-Finnish) ancestry and in 9 out of 17376
(0,052%) alleles from individuals of African ancestry (Lek
et al., 2016). It is evaluated as “likely benign” in ClinVar2.
Taking together, both variants are not pathogenic. Then an
important point to be addressed is whether the two variants in
SCN1B gene contributed to the occurrence of arrhythmias in
the BrS-patient.
It should be noted that the patient recruited for this
study carries the two variants in the same gene SCN1B
and suffered from recurrent syncope. BrS has been identified
by investigating family members using gene testing and
pharmacological study with ajmaline. The hiPSC-CMs generated
from the patient displayed reduced peak INa, reduced Vmax
2https://www.ncbi.nlm.nih.gov/clinvar/variation/190846/
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FIGURE 7 | Increased frequency by carbachol in BrS-cardiomyocytes. Single cell calcium transients were recorded in spontaneously beating cells with and without
challenge by 10 µM carbachol. The rhythm of beating cells were assessed and compared between BrS- and donor-cells. (A) Representative Ca2+ transients in a
donor (D1) cell in absence (at baseline) and presence of carbachol (CCh). (B) Representative Ca2+ transients in a BrS cell in absence (at baseline) and presence of
carbachol (CCh).
and increased arrhythmia like events, key features of BrS on
a cellular level. These data indicate that the two variants
of Leu210Pro and Pro213Thr in the SCN1B gene play
probably an important role for the pathogenesis of BrS
in that patient, which is inconsistent with aforementioned
evaluations. The reason for the disparity could be: (1) Some
gene variants are not pathogenic alone, but a co-factor can
enhance their pathogenicity; (2) Single variant and multiple
variants, especially in the same gene, may exert different
effects. It is well-known that only a small part of BrS-
patients have been proved to carry some gene mutations
that may be linked to the disease, suggesting involvement
of other unknown factors. Even in BrS-patients with known
pathogenic gene mutations, arrhythmias occur only under
certain conditions, suggesting involvement of some co-factor
effects. It could be possible that some gene mutations are
alone “benign,” but when some co-factor effects appear,
their effects (like reduced INa) may be enhanced and may
cause disease. Furthermore, if a single variant is “benign,”
it does not mean that a combination of two or more
variants is also “benign.” It could be possible that two or
more variants induce changes in a protein other than that
induced by a single variant. Our data showing reduced INa
and SCN1B expression in hiPSC-CMs from the BrS-patient
indicates that the two variants in SCN1B gene influenced
the protein expression and sodium channel gating, which
could be at least a mechanism for the arrhythmogenesis in
BrS. Moreover, the L-type calcium channel (ICa−L) and some
potassium channel (IKr and IKs) currents in iPSC-CMs from
the patient were also reduced, which resulted probably from
secondary changes induced by the SCN1B variants and could
contribute to the occurrence of arrhythmias in BrS. Not
only changes in channel currents but also in the expression
levels of channels (CACNA1C, KCNJ2, KCNH2, SCN1B, and
SCN3B) were observed (Supplementary Figure S1D), although
these results except for the SCN1B data should be further
confirmed at protein level. The changes in the expression
level of multiple ion channels indicated the existence of
ion channel remodeling in cardiomyocytes carrying the two
variants in SCN1B gene.
Furthermore, the L-type calcium channel (ICa−L)
and some potassium channel (IKr and IKs) currents in
iPSC-CMs from the patient were also reduced, which
resulted probably from secondary changes induced by the
SCN1B variants and could contribute to the occurrence of
arrhythmias in BrS.
It has been demonstrated that hiPSC-CMs can model BrS
with SCN5A mutations (Liang et al., 2016). Due to the lack of
studies on cellular characteristics of BrS patients with SCN1B
mutations using human cardiomyocytes, we aimed to investigate
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the cellular characteristics of a BrS patient carrying variants
in the SCN1B gene by using hiPSC-CMs. The SCN1B gene
encodes a ß-subunit of the sodium channel (termed Navβ1B)
and it can also influence gating of the pore-forming a-subunit
of sodium channels. It has been demonstrated that SCN1B
can enhance the sodium channel currents conducted by the
SCN5A channel (a-subunit). In the current study, the peak
sodium channel current and the late sodium channel current,
mediated mainly by SCN5A, were significantly decreased,
resulting from changed gating kinetics. Given that mutations
in SCN5A in our patient have been excluded, these changes
are caused probably by the two variants in SCN1B. Previously
published data have pointed to a possible interaction between
SCN5A and SCN1B by showing co-immunoprecipitation of
SCN5A and SCN1B in HEK cells (Hu et al., 2012). This
may help to understand our data from the current study
showing that the variants in SCN1B changed the gating
and led to a reduction of function of SCN5A channels
in BrS-hiPSC-CMs.
Besides, Hu et al. (2012) showed an interaction of SCN1B and
KCND3, a contributor of the Ito. Unfortunately, the present study
did not detect significant changes in Ito, although the Ikr and Iks
were significantly reduced.
Potassium current dysfunctions have been reported in BrS
related to the KCNE3 gene. In our patient, mutations in
potassium genes related to BrS were excluded. An imbalance
of INa and Ito (Vatta et al., 2002) may lead to heterogeneities
of action potential characteristics and may develop spatial
dispersion of repolarization as denominator for ventricular
tachycardia. In the current study, although we did not
observe enhanced outward currents including the Ito, we
did detect the reduction of INa, which may present the
important phenotypic changes in BrS. The reduced INa and
Vmax can reduce propagation of excitation, in agreement
with the conduction defect in BrS. In our study, we did
not observe significant changes of APD. This might be
explained by the counteracting effects of reduced inward
current (late INa) and outward currents (Ikr, IKs) on the
APD. In this and aforementioned studies, no APs with
spike and dome were detected probably because Ito was not
enhanced and spike and dome are related to gradient difference
between the epicard and endocard, which cannot be modeled
using hiPSC-CMs.
A further interesting finding of the present study is
the effect of ajmaline, which blocks sodium channel and
used to unmask BrS as a diagnostic challenge. Ajmaline
has shown an effect in both donor and BrS cells on
APA and Vmax. However, this effect was stronger in BrS
cardiomyocytes. This might confirm the higher sensitivity
of BrS patients with variants in SCN1B to sodium
channel blockers.
Finally, another interesting point of the study is the
effect of the parasympathetic stimulator carbachol (CCh),
which showed an opposite result as compared with healthy
donors. While in healthy donor cells after adding CCh
the beating frequency was reduced, in BrS cardiomyocytes
the beating frequency was significantly increased with
arrhythmic like events, which may reflect the induction of
ventricular tachyarrhythmias in BrS cardiomyocytes at resting
situation. Although carbachol mainly acts on muscarine
receptors (M1-2), it affects also beta-adrenergic receptors
causing a loss of receptors availability (Limas and Limas,
1985). Both effects should reduce the beating frequency
of cardiomyocytes, which was indeed observed in donor
cells challenged by CCh. Given that M3 receptors are also
expressed in hiPSC-CMs (Supplementary Figure S1E), we
speculate that CCh may stimulate M3 receptor and leads to
enhanced Ca2+ release or Ca2+ oscillations through Gq-PLC-
signaling. This may help understand why CCh increased the
frequency and abnormal Ca2+-transients, but cannot explain
why these effects of CCh were observed only in BrS cells
because no difference of expression levels of M-receptors
including M3, M3 and M4 was detected among donor
and BrS cells. The observed reduction of ß1 and elevation
of ß2 adrenoceptor expression cannot explain the effect
of CCh either. Therefore, how CCh increased the beating
frequency with arrhythmia-like events in BrS-hiPSC-CMs needs
to be clarified.
CONCLUSION
Our data demonstrated that the hiPSC-CMs from a BrS-patient
with SCN1B gene variants recapitulated the main features
of BrS, showing reduced INa, APA and Vmax, an increased
occurrence of arrhythmia-like events and enhanced sensitivity
to ajmaline challenge. The hiPSC-CM model may provide
a suitable platform for studying BrS and may be helpful
for drug screening.
STUDY LIMITATIONS
Differences among individuals of healthy probands cannot
be ruled out. Only one patient was recruited for this study
because we do not have a second patient with the same variants
and it should be very difficult to find another patient with
same variants in the same gene. This limitation cannot be
overcome before other patients with the same variants in
SCN1B are available. Anyway, the study is clinical relevant,
at least for personal medicine, which could be investigated
in future studies. HiPSC-CMs are differing from adult
human cardiomyocytes despite distinct similarities in their
physiological properties. The immaturity is a limitation
of hiPSC-CMs for mimicking the mature cardiomyocytes
in patients. However, most ion channels in hiPSC-CMs
including their electrical properties are similar to those
in mature cardiomyocytes. Therefore, it provides a good
opportunity to study ion channel functions under physiological
or pathological conditions. Furthermore, many intrinsic
mechanistic factors like nerve and hormone regulations
and cell to cell interaction are not considered, which might
be important in BrS. Finally, the spike and dome shape in
APs may contribute to forming the ECG-phenotype of BrS.
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The lack of APs with spike and dome of the present study
indicates a failure of hiPSC-CMs to recapitulate this feature of
BrS. However, it recapitulated other important features of BrS
including loss of function of SCN5A, reduced peak INa and
arrhythmogenesis.
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